Abbreviated name: TDF
Synonyms: (R)-PMPA | PMPA | tenofovir (anhydrous)
tenofovir is an approved drug
Compound class:
Synthetic organic
Comment: Tenofovir is a nucleotide reverse transcriptase inhibitor (NtRTI) antiretroviral compound. The R-enantiomer, as shown here, is more effective at inhibiting retroviruses than the S-enantiomer [1]. Tenofovir has poor oral bioavailability and is delivered as either the prodrug tenofovir disoproxil fumarate (Viread®) or tenofovir alafenamide fumerate (Vemlidy®).
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
Bioactivity Comments |
OAT1 and OAT3 in the basal membrane actively transport 20-30% of tenofovir into proximal tubule cells [3]. ABCC2 (MRP2) and ABCC4 (MRP4) at the apical surface secrete tenofovir into the tubular lumen [5]. |
Transporters Moving this Compound Across a Lipid Membrane | ||||||||||||||||||||
|
Targets where the ligand is described in the comment field | |
Target | Comment |
CoV RNA-dependent RNA polymerase | The conservation of RdRP catalytic domain between different RNA viruses endows inhibitors that were designed against other viral pathogens with activity against the SARS coronaviruses. Viral RdRP is the molecular target of nucleotide-based broad-spectrum antiviral compounds like remdesivir, tenofovir and ribavirin [4,6,8]. |